CLAIMS

1. Use of ~~vasoactive intestinal peptide (VIP) or~~ one or more functional vasoactive intestinal peptide (VIP) fragments selected from VIP(10-28), VIP(4-12), VIP(4-16), VIP(4-20), VIP(4-24), VIP(6-10), VIP(6-12), VIP(6-16), VIP(6-20), VIP(6-24) or conservative substitutions thereof, for the manufacture of a medicament for prophylactic or therapeutic treatment of kidney fibrosis.

2. The use according to claim 1, wherein the kidney fibrosis is associated with chronic kidney disease or kidney failure.

3. The use according to claim 1 or claim 2, wherein the medicament prevents, slows down or reduces the degree or intensity of kidney fibrosis.

4. The use of any one of claims 1 to 3, wherein the medicament further comprises one or more other agents active in the treatment of kidney fibrosis.

5. The use according to any one of claims 1 to 4, wherein the medicament reduces the levels, inhibits or reduces the production of pro-fibrotic mediators.

6. The use according to any one of claims 1 to 5, wherein the medicament reduces collagen formation or enhances collagen degradation.

7. The use according to any one of claims 1 to 6, wherein the medicament prevents or slows down the development of fibrosis or reduces the degree of established fibrosis.

8. The use according to any one of claims 1 to 7, wherein the medicament is formulated for administration by oral, intravenous, intramuscular or subcuticular routes.

9. The use according to any one of claims 1 to 8, wherein the medicament reduces the risk of developing, prevents establishment of, or slows progression of kidney fibrosis.